Stifel Reiterates Buy Rating on Freeline (FRLN), Sees FLT190 Updates as Positive, but Needs More Clearance into True Therapeutic Benefit
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating on Freeline (NASDAQ: FRLN), following the company's recent update on FLT190 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
